Multiple Sclerosis (MS) Drugs - Global Market Projections to 2023: Key Players are Bayer, Biogen, Merck, Novartis, and Sanofi - ResearchAndMarkets.com

The "Global Multiple Sclerosis Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The multiple sclerosis drugs market will register a CAGR of close to 6% by 2023.

Globally, the prevalence of multiple sclerosis has increased due to genetic and environmental factors. Another reason which could be attributed to the increasing prevalence is the advances in diagnostic techniques in this therapy area.

The prevalence of autoimmune diseases such as type 1 diabetes and certain infections such as infectious mononucleosis also increases the risk of multiple sclerosis. In 2008, the global prevalence of multiple sclerosis was estimated to be 0.031%, which increased to 0.032% in 2013.

The prevalence of multiple sclerosis in Europe is also high. High disease prevalence drives the demand for drugs, thereby driving the growth of the market.

Strong drug pipeline

With the increase in the prevalence of multiple sclerosis, there is a high unmet need for a strong pipeline of disease-modifying drugs. Current drugs for multiple sclerosis slow down the disease progression, but in many patients' responses to drugs are often variable and suboptimal.

Ongoing R&D for the development of new drugs has resulted in the development of a strong drug pipeline for the treatment of multiple sclerosis. Therefore, the drug development initiatives by companies are expected to dive the market in the forecast period.

Side effects of multiple sclerosis drugs

The side effects associated with multiple sclerosis drugs can range from mild to serious. Therefore, side effects associated with these drugs can lead to low patient compliance and may hinder the growth of the global multiple sclerosis drugs market.

Competitive Landscape

The market appears to be moderately concentrated and with the presence of limited vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Key Players

• Bayer
  
• Biogen
• Merck
  
• Novartis
  
• Sanofi

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

• Market ecosystem
• Market characteristics
• Market segmentation analysis

PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING

• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023

PART 06: FIVE FORCES ANALYSIS

PART 07: MARKET SEGMENTATION BY TYPE

• Comparison by type
• Oral - Market size and forecast 2018-2023
• Parenteral - Market size and forecast 2018-2023
• Market opportunity by type

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

• Geographic comparison
• North America - Market size and forecast 2018-2023
• Europe - Market size and forecast 2018-2023
• Asia - Market size and forecast 2018-2023
• RoW - Market size and forecast 2018-2023
• Key leading countries
• Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

• Overview
• Landscape disruption

PART 14: VENDOR ANALYSIS

• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bayer AG
• Biogen
• Merck KGaA
• Novartis AG
• Sanofi

For more information about this report visit https://www.researchandmarkets.com/research/6vdggh/multiple?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190322005204/en/